dual path

Aggressive lipid lowering superior to usual care in a real-world setting: The ALLIANCE study

dual path

Exam

Dual inhibition effective and safe in clinical practice: The EASE study

Managed Care Commentary:MCOs face new challenges

Phytosterols may play role in atherosclerosis

Blocking intestinal cholesterol absorption for optimal lipid lowering

Dual pathway inhibition: Attacking cholesterol on two fronts

Beyond ATP III-Impact of recent clinical trials on future lipid management guidelines and therapeutic goals

Future Goals, Targets, and Treatments of Dyslipidemia